Search 14,028 Media Articles
In 2018, still in the throes of painful withdrawal from a psychiatric drug cocktail, U.S. Air Force veteran Derek Blumke began connecting the dots. He heard horror story after horror story that followed a disturbingly familiar pattern: starting, adjusting the dose, or abruptly stopping antidepressants was followed by personality changes, outbursts and acts of violence or suicide, leaving countless families and lives destroyed. Timothy Jensen ... an Iraq war veteran who served in the Marines, had been researching psychiatric drug overprescribing in the Veterans’ Health Administration (VA) system for years. He had his own harrowing personal story of antidepressant harm, and he had lost his best friend, a fellow veteran, to suicide soon after he was prescribed Wellbutrin for smoking cessation. Poring through the data, Blumke landed on some startling statistics: 68% of all veterans seen at least one time for care at the VA in 2019 had been prescribed psychotropic drugs, and 28% were issued prescriptions for antidepressants. “It should be zero shock that veterans have the suicide rates we do,” Blumke said. “Veteran suicide rates are two to two and a half times that of the civilian population. Prescription rates of antidepressants and psychiatric drugs are of the same multiples, which are both the highest in the world.” Antidepressants and other psychotropic drugs have huge risk profiles, but doctors and counselors aren’t even being trained about these issues.
Note: Suicide among post-9/11 veterans rose more than tenfold from 2006 to 2020. Why is Mad in America the only media outlet covering this important issue affecting so many veterans? Along these lines, the UK’s medicines regulator is launching a review of over 30 commonly prescribed antidepressants, including Prozac, amid rising concerns about links to suicide, self-harm, and long-term side effects like persistent sexual dysfunction—especially in children.
We urgently need a national debate about guns. But we also urgently need a national debate about the epidemic of mood-altering drugs being prescribed to young Americans. Mass shooters in the United States tend to be young, obsessive, male loners and many have been prescribed psychoactive drugs. For example, Eric Harris, one of the two shooters at Columbine High School in Columbine, Colorado, in 1999—which ushered in the current spate of mass shootings—was on the psychotropic drug Luvox. Prescribing information for the antidepressant says, “Close supervision of patients and in particular those at high risk should accompany drug therapy.” Jeff Weise, who fatally shot his grandfather, his grandfather’s girlfriend, and then seven others at the Red Lake Senior High School in Minnesota in 2005, was on the well-known antidepressant Prozac. Two years later, Cho Seung-Hui, who perpetrated the Virginia Tech mass shooting, also was found to be on psychoactive antidepressants. Jeanne Stolzer, associate professor of child and adolescent development at the University of Nebraska-Kearney, observes that “despite the multitude of international drug regulatory warnings on all classifications of psychiatric medications citing adverse reactions such as suicidal ideation, homicidal ideation, violence, and psychosis, not one local, state, or federal commission has investigated the correlation between the mass shootings in America and the use of psychiatric medications.”
Note: Although Epoch Times is often deemed as a controversial media platform, this article raises legitimate questions on an important topic seldom discussed. Read a revealing article that investigates the alarming adverse events associated with common mood-altering medications prescribed for those struggling with mental illness. For more on this concerning trend, consider exploring an in-depth article written by an anonymous doctor who reveals the decades of evidence showing how adverse reactions from psychiatric drugs can manifest as both suicides and homicides.
Prozac, the bestselling antidepressant taken by 40 million people worldwide, does not work and nor do similar drugs in the same class, according to a major review released today. The study examined all available data on the drugs, including results from clinical trials that the manufacturers chose not to publish at the time. The trials compared the effect on patients taking the drugs with those given a placebo or sugar pill. When all the data was pulled together, it appeared that patients had improved - but those on placebo improved just as much as those on the drugs. The only exception is in the most severely depressed patients, according to the authors - Prof Irving Kirsch from the department of psychology at Hull University and colleagues in the US and Canada. But that is probably because the placebo stopped working so well, they say, rather than the drugs having worked better. "Given these results, there seems little reason to prescribe antidepressant medication to any but the most severely depressed patients, unless alternative treatments have failed," says Kirsch. "This study raises serious issues that need to be addressed surrounding drug licensing and how drug trial data is reported." The paper, published today in the journal PLoS (Public Library of Science) Medicine, is likely to have a significant impact on the prescribing of the drugs. The National Institute for Health and Clinical Excellence already recommends that counselling should be tried before doctors prescribe antidepressants.
Note: For many key reports on health issues from reliable sources, click here.
Marie began taking fluoxetine, the generic form of Prozac, when she was 15. The drug — an S.S.R.I., a selective serotonin reuptake inhibitor — was part of her treatment in an outpatient program for an eating disorder. It took its toll on her sexuality. Marie told me she has PSSD, post-S.S.R.I. sexual dysfunction, a loss of sexuality that persists after the drug is no longer being taken. Clinicians have published more than 500 case reports in academic literature about the experience of PSSD. A 2020 editorial in The British Medical Journal argued, “Post-S.S.R.I. sexual dysfunction is underrecognized and can be debilitating both psychologically and physically.” The effects of S.S.R.I.s on young sexuality are all the more relevant because prescriptions for the drugs have soared. Around two million 12-to-17-year-olds in the United States are on S.S.R.I.s. One large 2024 study ... tallied, month by month, the percentage of that age group who filled an antidepressant prescription between 2016 and 2022. During that time, the rate climbed by 69 percent. There are no dedicated studies of sexual side effects among the young. All that is available is extrapolation from research among adults. Depending on the symptom, drug and duration of use, between 30 and 80 percent of adults taking S.S.R.I.s live to varying degrees with diminished desire, sensation and function, according to a 2019 study.
Note: For more along these lines, read our concise summaries of news articles on Big Pharma profiteering and mental health.
Medical experts and politicians have called for the amount of antidepressants being prescribed to people across the UK to be reduced in an open letter to the government. The letter coincides with the launch of the all-party parliamentary group Beyond Pills, which aims to reduce what it calls the UK healthcare system’s over-reliance on prescription medication. A total of 8.6 million patients in England were prescribed antidepressants in 2022-23, with the amount having almost doubled since 2011. Published in the British Medical Journal ... the letter says: “Rising antidepressant prescribing is not associated with an improvement in mental health outcomes at the population level, which, according to some measures, have worsened as antidepressant prescribing has risen.” The letter goes on to say that reducing the rate of antidepressant prescriptions could be achieved through measures that includes stopping the prescribing of antidepressants for mild conditions, and funding and delivering a national 24-hour prescribed drug withdrawal helpline ... to help those experiencing withdrawal symptoms from prescription medication. [Former chief executive of NHS England, Nigel] Crisp said: “The high rate of prescribing of antidepressants over recent years is a clear example of over-medicalisation, where patients are often prescribed unnecessary and potentially harmful drugs instead of tackling the root causes of their suffering, such as loneliness, poverty or poor housing.
Note: Antidepressants are some of the most commonly prescribed medications, yet their significant risks are often withheld from public debate. For more along these lines, see concise summaries of deeply revealing news articles on health and Big Pharma corruption from reliable major media sources.
The US Food and Drug Administration approved Janssen Pharmaceuticals Inc.'s esketamine on Tuesday for treatment-resistant depression; the drug is the chemical cousin of ketamine, the powerful anesthetic that has been used illegally as the club drug Special K. It will be sold as Spravato. It's for patients who have tried at least two other medications without success, and it should be taken with an oral antidepressant. "There has been a longstanding need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition," Dr. Tiffany Farchione, acting director of the Division of Psychiatry Products at the FDA's Center for Drug Evaluation and Research, said. Spravato is a nasal spray administered by an approved health care provider in a doctor's office or a medical clinic. It may also be self-administered but only under the supervision of a care provider and cannot be taken home. Depending on the severity of the patient's depression, it is given either once a week or once every other week. The drug is rapidly acting, so it starts working faster than other antidepressants, according to Janssen. It works by restoring brain cells in patients with treatment-resistant depression. Currently available treatments for major depression are ineffective in 30% to 40% of patients. The drug was designated as a breakthrough therapy in 2013, a status intended to "expedite the development and review of drugs for serious or life-threatening conditions," the FDA said at the time.
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
Outro Health [is] a telehealth startup that CEO and cofounder Brandon Goode describes as “Uber for getting off antidepressants.” Outro officially launched in the US last month and is currently available in seven states. The startup is betting that many of the growing number of Americans taking antidepressants will eventually want help coming off them. Over 11 percent of US adults took medication for depression in 2023. Research has found the prevalence of adverse withdrawal symptoms may be much higher, particularly among patients who have been on them for long periods. Outro pairs patients with a clinician who meets with them on a custom schedule and guides them through a tailored tapering program. Outro currently employs a small group of medical contractors, including nurse practitioners specializing in psychiatry and general nurse practitioners, who are supervised by psychiatrists. [British academic psychiatrist and co-founder of Outro] Mark Horowitz ... was driven by his own harrowing experience coming off antidepressants ... when he was a psychiatry doctoral student. Severe insomnia and dizziness were so debilitating ...It took me years to come off, not weeks as guidelines recommended.” After he recovered, Horowitz began pushing for doctors to adopt new clinical guidelines for getting off antidepressants. He coauthored the Royal College of Psychiatry's guidance for psychiatric drug cessation and joined the UK’s National Health Service as a clinical research fellow. “To me, it is actually a very leftist issue to de-medicalize the way we treat anxiety and depression,” [Horowitz] says, noting that such illnesses are often caused “by social circumstances, by poverty, by loneliness.”
Note: For more along these lines, read our concise summaries of news articles on Big Pharma corruption and mental health.
Antidepressants are frequently prescribed to people with dementia for symptoms like anxiety, depression, aggressiveness and sleeplessness. But a specific class of antidepressant medications - selective serotonin reuptake inhibitors (SSRIs) - actually might speed up brain decline among some dementia patients, a new Swedish study suggests. Heavier doses of certain SSRIs are tied to a higher risk for severe dementia, researchers reported in a new study ... in the journal BMC Medicine. The SSRI drug escitalopram was associated with the fastest cognitive decline, followed by citalopram and sertraline. For the study, researchers tracked the brain health of more than 18,700 patients enlisted in the Swedish Registry for Cognitive/Dementia Disorders between May 2007 and Oct. 2018. The patients’ average age was 78. During an average follow-up of more than four years, about 23% of patients received a new prescription for an antidepressant, researchers said. SSRIs were the most commonly prescribed antidepressant, amounting to 65% of all those prescriptions, the study says. “Higher dispensed doses of SSRIs were associated with higher risk for severe dementia, fractures, and all-cause mortality,” the researchers concluded. “These findings highlight the significance of careful and regular monitoring to assess the risks and benefits of different antidepressants use in patients with dementia.”
Note: For more along these lines, read our concise summaries of news articles on Big Pharma corruption.
Hallucination-inducing drugs like magic mushrooms could be about to break big pharmas stranglehold on the hugely lucrative market for antidepressants, according to the head of the worlds first centre for psychedelic research. Antidepressant prescriptions have doubled in England in a decade with around seven million adults taking the drugs, and the global market is predicted to be worth $15.9bn (12.5bn) by 2023. At Imperial College London, Dr Robin Carhart-Harris is leading one of the first trials to test how therapy using psilocybin mushrooms, which are currently banned in the UK, compares to leading antidepressants. While he wont prejudge the results of the study, he says participants describe a cathartic emotional release with psilocybin therapy the polar opposite of antidepressants, which patients complain leave their emotions, whether positive or negative, blunted. It is the first of many studies planned under the banner of the new Centre for Psychedelic Research at Londons Imperial College. Dr James Rucker is another of those researching the potential benefits of psychedelics ... at Kings College London. The Kings team are launching two trials, one looking at whether psilocybin therapy can help people whose depression is resistant to treatment with conventional antidepressants. He says it was possible the drug could be licensed in five years.
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
Psychologist and best-selling author Shawn Achor has made a career studying the science of happiness. "Scientifically, happiness is a choice," Achor says. He explains that research has shown you can rewire your brain to make yourself happy by practising simple happiness exercises. Achor says in just 21 days, the exercises can transform a pessimist into an optimist. And within 30 days, those habits change the neuropathways of our brains and turn us into lifelong optimists. These six daily happiness exercises are proven to make anyone, from a 4-year old to an 84-year old, happy, or simply happier, Achor says: 1. Gratitude Exercises. Write down three things you're grateful for that occurred over the last 24 hours. They don't have to be profound. 2. The Doubler. Take one positive experience from the past 24 hours and spend two minutes writing down every detail about that experience. As you remember it, your brain labels it as meaningful and deepens the imprint. 3. The Fun Fifteen. Do 15 minutes of a fun cardio activity, like gardening or walking the dog, every day. The effects of daily cardio can be as effective as taking an antidepressant. 4. Meditation. Every day take two minutes to stop whatever you're doing and concentrate on breathing. 5. Conscious act of kindness. At the start of every day, send a short email or text praising someone you know. 6. Deepen Social Connections. Spend time with family and friends.
Note: The three-minute video at the link above link has some good ideas on achieving greater happiness. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
In a rare move, the Justice Department on Tuesday announced that it had charged a former vice president and top lawyer for the British drug giant GlaxoSmithKline with making false statements and obstructing a federal investigation into illegal marketing of the antidepressant Wellbutrin for weight loss. “This is absolutely precedent-setting — this is really going to set people’s hair on fire,” said Douglas B. Farquhar, a Washington lawyer. “This is indicative of the F.D.A. and Justice strategy to go after the very top-ranking managing officials at regulated companies.” The indictment accuses the Glaxo official, Lauren C. Stevens of Durham, N.C., of lying to the Food and Drug Administration in 2003, by writing letters, as associate general counsel, denying that doctors speaking at company events had promoted Wellbutrin for uses not approved by the agency. Ms. Stevens “made false statements and withheld documents she recognized as incriminating,” including slides the F.D.A. had sought during its investigation, the indictment stated. The company was cooperating fully with a federal investigation into allegations of illegal sales and marketing of Wellbutrin. Last year, it set aside $400 million to resolve the case, which is still pending. Two weeks ago, in an unrelated case, GlaxoSmithKline agreed to pay $750 million to the government to settle civil and criminal complaints that it sold tainted or ineffective products from a large manufacturing facility in Puerto Rico.
Note: Even with fines in the hundreds of millions of dollars assessed to many of the large pharmaceuticals, why isn't more being done? See what one of the top doctors in the US revealed about corruption in health care at this link.
GlaxoSmithKline, the British drug giant, has agreed to pay $750 million to settle criminal and civil complaints that the company for years knowingly sold contaminated baby ointment and an ineffective antidepressant — the latest in a growing number of whistle-blower lawsuits that drug makers have settled with multimillion-dollar fines. Altogether, GlaxoSmithKline sold 20 drugs with questionable safety that were made at a huge plant in Puerto Rico that for years was rife with contamination. Cheryl D. Eckard, the company’s quality manager, asserted in her whistle-blower suit that she had warned Glaxo of the problems but the company fired her instead of addressing them. Among the drugs affected were Paxil, an antidepressant; Bactroban, an ointment; Avandia, a troubled diabetes drug; Coreg, a heart drug; and Tagamet, an acid reflux drug. Justice Department officials announced the settlement in a news conference Tuesday afternoon in Boston, saying a $150 million payment to settle criminal charges was the largest such payment ever by a manufacturer of adulterated drugs. The outcome also provides $600 million in civil penalties. The share to the whistle-blower will be $96 million, one of the highest such awards in a health care fraud case.
Note: For key reports from major media sources on corporate corruption and criminality, click here.
Doctors and patients are being misled about the effectiveness of some drugs because negative trial results are not published, experts have warned. Writing in the British Medical Journal, they say that pharmaceutical companies should be forced to publish all data, not just positive findings. The German team give the example of the antidepressant reboxetine, saying publications have failed to show the drug in a true light. Reboxetine (Edronax), made by Pfizer, is used in many European countries, including the UK. But its rejection by US drug regulators raised doubts about its effectiveness, and led some to hunt for missing data. This is not the first time a large drug company has come under fire about its published drug trial data. Pharmaceutical giant GlaxoSmithKline (GSK) was criticised for failing to raise the alarm on the risk of suicidal behaviour associated with its antidepressant Seroxat. GSK has also been forced to defend itself over allegations about hiding negative data regarding another of its drugs, Avandia, which is used to treat diabetes. "Our findings underline the urgent need for mandatory publication of trial data," [the researchers] say in the BMJ. They warn that the lack of all information means policy makers are unable to make informed decisions. In the US, it is already a requirement that all data - both positive and negative - is published.
Note: For a powerful summary of government/corporate corruption in the pharmaceutical industry by a respected former editor of a major medical journal, click here.
A breathing-based meditation practice known as Sudarshan Kriya yoga helped alleviate severe depression in people who did not fully respond to antidepressant treatments, reports a new study published in the Journal of Clinical Psychiatry. Researchers found significant improvement in symptoms of depression and anxiety in medicated patients with major depressive disorder (MDD) who participated in the breathing technique compared to medicated patients who did not partake. More than half of the 41 million Americans who take antidepressants do not fully respond. Add-on therapies are often prescribed to enhance the effects of the drugs in these patients, but they typically offer limited additional benefits and come with side effects that can [prolong] the depressive episode. The meditation technique ... includes a series of sequential, rhythm-specific breathing exercises that bring people into a deep, restful, and meditative state: slow and calm breaths alternated with fast and stimulating breaths. In past studies, the practice has demonstrated a positive response in patients with milder forms of depression, depression due to alcohol dependence, and in patients with MDD; however, there are no clinical studies investigating its use for depression in an outpatient setting. Past studies suggest that yoga and other controlled breathing techniques can potentially adjust the nervous system to reduce stress hormones.
Note: Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
When the drug industry came under fire last summer for failing to disclose poor results from studies of antidepressants, major drug makers promised to provide more information about their research on new medicines. But nearly a year later, crucial facts about many clinical trials remain hidden. Eli Lilly and some other companies have posted hundreds of trial results on the Web and pledged to disclose all results for all drugs they sell. But other drug makers, including Merck and Pfizer, release less information and are reluctant to add more, citing competitive pressures. As a result, doctors and patients lack critical information about important drugs ... and the companies can hide negative trial results by refusing to publish studies, or by cherry-picking and highlighting the most favorable data. GlaxoSmithKline agreed to pay $2.5 million to settle a suit ... alleging that Glaxo had hidden results from trials showing that its antidepressant Paxil might increase suicidal thoughts in children and teenagers. Federal laws require the disclosure of all trials and trial results to the F.D.A. But companies are not required to disclose trial results to scientists or the public. Under pressure from the editors of medical journals, the major drug companies in January agreed to expand the number of trials registered on clinicaltrials.gov. Three companies have filed only vague descriptions of many studies, often failing even to name the drugs under investigation. For example, Merck describes one trial as a "one-year study of an investigational drug in obese patients."
A psychedelic drink used for centuries in healing ceremonies is now attracting the attention of biomedical scientists as a possible treatment for depression. Researchers from Brazil last month published results from the first clinical test of a potential therapeutic benefit for ayahuasca, a South American plant-based brew. The work forms part of a renaissance in studying the potential therapeutic benefits of psychedelic or recreational drugs research that was largely banned or restricted worldwide half a century ago. Ketamine, which is used medically as an anaesthetic, has shown promise as a fast-acting antidepressant; psilocybin, a hallucinogen found in magic mushrooms, can help to alleviate anxiety in patients with advanced-stage cancer; MDMA (ecstasy) can alleviate post-traumatic stress disorder; and patients who experience debilitating cluster headaches have reported that LSD eases their symptoms. Ayahuasca, a sacramental drink traditionally brewed from the bark of a jungle vine (Banisteriopsis caapi) and the leaves of a shrub (Psychotria viridis) ... has been studied by anthropologists, social scientists and theologians, but clinical research on ayahuasca has been limited to observation of its effects in mice and rats, and in healthy human volunteers, including brain-imaging studies and retrospective surveys of past use. Further trials are under way.
Note: Are the healing potentials of mind altering drugs finally starting to receive honest mainstream attention?
While [Ketamine] has been used as an anesthetic for decades, small studies at prestigious medical centers like Yale, Mount Sinai and the National Institute of Mental Health suggest it can relieve depression in many people who are not helped by widely used conventional antidepressants like Prozac or Lexapro. And the depression seems to melt away within hours, rather than the weeks typically required for a conventional antidepressant. Pharmaceutical companies hope to [develop] drugs that work like ketamine but without the side effects, which are often described as out-of-body experiences. Some doctors and patients are not waiting for the pharmaceutical industry. Because ketamine has long been approved for anesthesia, doctors are allowed to use it off-label to treat depression. There is clearly a need for new drugs. Almost half of depressed patients are not being treated adequately by existing drugs, said Dr. Sheldon H. Preskorn, a professor of psychiatry at the University of Kansas School of Medicine-Wichita. That, he said, is because virtually all the antidepressants used in the last 60 years work essentially the same way. Ketamine would represent a new mechanism of action. Synaptic connections that help us to cope seem to grow back, said Dr. John H. Krystal, chairman of psychiatry at Yale and a pioneer in the study of ketamine for depression.
Note: A 2012 NPR story provides more detail about the ketamine research done at Yale to treat depression. Could this put a stop to the thousands of horror stories involving conventional antidepressants?
For the second time in two months, The Journal of the American Medical Association says it was misled by researchers who failed to reveal financial ties to drug companies. The latest incident, disclosed in letters to the editor and a correction in Wednesday's journal, involves a study showing that pregnant women who stop taking antidepressants risk slipping back into depression. Most of the 13 authors have financial ties to drug companies including antidepressant makers, but only two of them revealed their ties when the study was published in February.
Note: To understand how the drug companies manipulate results and even exert tremendous influence over the U.S. Congress, see http://www.WantToKnow.info/healthcoverup
It's the conundrum that faces all television personalities broadcasting live: how to deal with hecklers trying to disrupt the show. Do you ignore the perpetrators? Do you try to reason with them? Or do you do what the American comic and talk show host Bill Maher did - jump into the audience, threaten the hecklers with an "ass kicking" and scream "Get the fuck out of my building!" In one of the more unconventional displays of audience interaction on US television in recent years, that is now doing hot trade as a clip on YouTube, Maher reacted to the interruptions of hecklers in his studio audience with the memorable words: "Do we have some fucking security in this building?" He then tore off his lapel microphone and stormed off the stage and up to some protesters wielding "expose the 9/11 cover-up" banners. It was at that point during a panel discussion on his HBO show, Real Time With Bill Maher, that the nature of the comic's difficulties with an element of his audience became clear. Maher is a darling of the US liberal intelligentsia for his brand of Bush-bashing and anti-religious pedantry. But the one point over which he will not bash the Bush administration is the events of September 11 2001. He does not agree with 9/11 conspiracy theorists, or Truthers as they call themselves, that the Bush administration brought down the Twin Towers in a controlled explosion. The trouble started a few weeks ago when Maher launched a verbal assault on air against the Truthers, calling them "crazy people". He advised the conspiracy theorists, who had been demonstrating outside his studio, to visit their doctor to ask whether the antidepressant Paxil was right for them. In 2002 ABC ended its relationship with him over comments he made in his former show, Politically Incorrect, about the 9/11 hijackers.
Note: To watch Bill Maher's performance on YouTube, click here. For a concise summary of reliable reports from major media sources which raise many unanswered questions about what really happened on 9/11, click here.
Exposure to dirt may be a way to lift mood as well as boost the immune system, UK scientists say. Lung cancer patients treated with "friendly" bacteria normally found in the soil have anecdotally reported improvements in their quality of life. Mice exposed to the same bacteria made more of the brain's "happy" chemical serotonin, the Bristol University authors told the journal Neuroscience. A lack of serotonin is linked with depression in people. The scientists say more work is now needed to determine if the bacterium Mycobacterium vaccae has antidepressant properties. Lead researcher Dr Chris Lowry said: "These studies help us understand how the body communicates with the brain and why a healthy immune system is important for maintaining mental health. They also leave us wondering if we shouldn't all spend more time playing in the dirt." The work could also help experts' understanding of why an imbalance in the immune system leaves some individuals vulnerable to mood disorders like depression, he added.
